Collaboration with COR2ED – HCC CONNECT
DiCE is pleased to collaborate with COR2ED, a provider of Independent Medical Education. To stay up-to-date in Hepatocellular Carcinoma (HCC) please visit the COR2ED website to view these 2 educational programmes:
Experts Knowledge Share: Treatment Options for HCC Patients Not Eligible for or Progressed on IO
Watch the video of experts discussing immunotherapy (IO) as a 1st-line treatment for advanced HCC and options if patients are not eligible for 1st-line IO. The panel also addresses the right time to switch to 2nd-line treatments. The video ends with an engaging Q&A where the experts answer pressing questions. The video has been divided into four digestible chapters.
Micro-learning: The Use of Immunotherapy in HCC
|
This accredited micro-learning consists of two modules. Each module includes a short, animated video and downloadable resources. Module 1 covers the efficacy and safety of IO and IO combinations and where they fit in the treatment landscape, how to understand the survival curve and how to identify and manage immune-related adverse events (irAE). Module 2 focuses on subgroup analyses and explains how to assess liver function using the Albumin-Bilirubin (ALBI) scoring system to evaluate a patient’s eligibility for IO treatment and how to understand the safety and efficacy data in the different subgroups.
|
|
|
|
|
Lili Gundelach
